Inotuzumab ozogamicin tied to sinusoidal obstruction syndrome in ALL

FROM LANCET HAEMATOLOGY Inotuzumab ozogamicin therapy significantly increased the risk of sinusoidal obstruction syndrome ...

Big changes coming for thyroid cancer staging

EXPERT ANALYSIS FROM WCTC 2017 BOSTON (FRONTLINE MEDICAL NEWS) – When the American Joint ...

Inotuzumab ozogamicin approved for relapsed/refractory ALL

The Food and Drug Administration has approved the antibody drug conjugate inotuzumab ozogamicin for ...

Vitamin D level linked to post-alloSCT relapse risk in myeloma

FROM JCO Patients with myeloid malignancies who have vitamin D deficiency prior to an ...

Crizotinib shows responses in pediatric ALCL and IMT

FROM JOURNAL OF CLINICAL ONCOLOGY Treatment with the ALK-inhibitor crizotinib produced high response rates ...

Lenalidomide maintenance boosts survival in de novo myeloma after ASCT

FROM JCO Patients with newly diagnosed multiple myeloma who received lenalidomide as maintenance therapy ...

Hospice care underused in older patients with de novo AML

FROM JOURNAL OF CLINICAL ONCOLOGY Although adults older than 65 newly diagnosed with acute ...

Revised thyroid Bethesda System resets malignant risks

EXPERT ANALYSIS FROM WCTC 2017 BOSTON (FRONTLINE MEDICAL NEWS) – Under the newly revised ...